Changing transmission patterns of mpox prompted changes in California’s containment strategy, while locally acquired Chagas disease and recurrent malaria infections highlighted surveillance and treatment challenges, speakers reported at IDWeek 2026.
Mpox response changes with transmission patterns
Kathleen Jacobson, MD, chief of the Office of Sexually Transmitted Infections and Hepatitis C at the California Department of Public Health, explained how the state's mpox response shifted from enhanced containment of sporadic introductions to a routine response as community transmission emerged. Her presentation focused on clade Ib, a subclade of the monkeypox virus that causes mpox.
Clade Ib mpox cases increased rapidly in eastern areas of the Democratic Republic of the Congo in late 2023, followed by mostly travel-associated infections in other countries in 2024. In November 2024, the first U.S. clade Ib infection was reported in California in a patient with recent international travel.
The initial response included tracing 81 contacts, including 65 health care workers, conducting daily symptom monitoring for 21 days and providing postexposure prophylaxis to high- and intermediate-risk contacts, Dr. Jacobson said. No secondary transmission was identified.
California also established surveillance flags for positive orthopoxvirus or mpox test results accompanied by negative or indeterminate clade II results. State laboratory staff requested specimens for clade I testing to identify introductions early.
In October 2025, three clade Ib infections in patients without international travel or identified epidemiologic links to one another suggested possible community transmission, Dr. Jacobson said, citing a report in NEJM Evidence. California continued its containment strategy, and no additional patients with clade Ib infection had been identified through the end of November 2025.
In August 2026, monthly U.S. clade Ib cases exceeded clade IIb cases for the first time, Dr. Jacobson said. By October 2026, more than 90 laboratory-confirmed clade Ib infections had been reported across the U.S., predominantly among gay, bisexual and other men who have sex with men. More than 10 jurisdictions had reported presumed domestic transmission. Dr. Jacobson said CDC had described a likely transition to sustained clade Ib transmission.
California subsequently assessed its enhanced containment activities. Approximately 90% of 24 interviewed patients were already isolating. Investigators identified 121 contacts, including eight classified as high risk. Two secondary infections occurred, both among high-risk contacts.
“We didn’t really add much to what they themselves were doing,” Dr. Jacobson said of patients’ existing isolation practices. California ended its enhanced containment activities and shifted to the approach used for clade II mpox, she said.
Vaccination remained another component of the response. Dr. Jacobson emphasized that the two-dose mpox vaccine could be given to patients with HIV regardless of CD4 count and to patients taking immunosuppressive medications.
California expanded its vaccination recommendations to include patients anticipating sexual or intimate contact during international travel, particularly to countries with person-to-person clade I transmission.
Dr. Jacobson said the main lessons from the outbreaks included engaging affected communities to inform policy, adapting public health responses to community needs and changing transmission patterns, investing in public health infrastructure and preparedness and ensuring global vaccine access.
“And global communication around evolving disease dynamics is also important because it helps us stop and reassess what we’re doing,” she said.
Chagas surveillance connects human and animal health
Sarah Hamer, DVM, PhD, professor of epidemiology at Texas A&M University’s College of Veterinary Medicine and Biomedical Sciences, described how vector and animal investigations can identify settings where patients may be exposed to Trypanosoma cruzi, the parasite that causes Chagas disease.
Triatomine insects, or kissing bugs, can transmit the parasite when infected fecal material enters a host through mucous membranes or a bite site. Oral transmission can also occur through contaminated food or ingestion of infected insects, Dr. Hamer said.
"Although it's hard to show with data, many veterinarians suspect oral transmission is likely responsible for many of the dog infections across the southern U.S., when dogs inadvertently consume infected kissing bugs,” she said.
Her laboratory’s community science program, launched in 2013, had received more than 10,000 kissing bugs through 2025, with most submissions coming from Texas. More than 50% of tested adult insects were infected with T. cruzi.
The program offers free identification and parasite testing and documents when and where people encounter the insects. Submissions involving insects found in bedrooms or implicated in human bites trigger efforts to connect the submitter with a state health department when an appropriate referral program exists.
Blood meal analysis also demonstrated the vectors’ broad host range. Of 123 insects from dog kennels with vertebrate DNA amplified from their guts, 118 produced deep-sequencing results, with multiple hosts identified in most insects. Detected hosts included dogs, humans, wildlife, birds and reptiles.
“These are truly opportunistic vectors that will feed broadly on whatever is available to them,” Dr. Hamer said.
She illustrated the clinical relevance with a case published in Clinical Infectious Diseases of an infant in Three Rivers, Texas, south of San Antonio, who developed acute Chagas disease with fulminant myocarditis in fall 2025. The patient had never traveled outside Texas, the parents had never traveled internationally and kissing bugs had been seen inside the home. The family reported that the infant had played with crushed insect remains.
Investigators sampled blood from 21 domestic animals for serologic and polymerase chain reaction testing and collected kissing bugs at the home. A cat, rabbit and miniature horse had T. cruzi DNA detected in blood. Investigators collected 20 kissing bugs; eight of 13 tested insects were infected.
Dr. Hamer noted limitations in veterinary Chagas disease diagnosis, including imperfect diagnostic tests for many animal species and limited awareness among pet owners and veterinarians. Her team aims to use ecological, vector and animal data to raise awareness of locally acquired human infection and identify areas for priority surveillance. Ongoing research in naturally infected dogs may also inform interventions, although adherence, attrition, coinfections and other illnesses complicate those studies, she said.
Malaria guidance extends treatment course
Alison Ridpath, MD, MPH, a medical epidemiologist in the Malaria Branch at CDC, discussed updated treatment guidance informed by reports of recurrent malaria infections.
CDC recommends a five-day, 10-dose course of artemether-lumefantrine when used to treat uncomplicated Plasmodium falciparum malaria in the U.S., Dr. Ridpath said. The extended course is also recommended when artemether-lumefantrine is used after intravenous artesunate for severe P. falciparum malaria. The three-day course remains recommended when artemether-lumefantrine is used for other confirmed malaria species.
The update followed a review of treatment failures reported to CDC and published evidence on failures among travelers and the efficacy and safety of extended regimens, along with discussions with an external expert committee.
From November 2022 through October 2025, CDC identified 40 possible treatment failures involving artemether-lumefantrine, with or without intravenous artesunate. All patients had traveled to Africa, most to West Africa, Dr. Ridpath said.
Late treatment failures, or recrudescence, accounted for 85% of these failures. Among patients with late failures, 10 received intravenous artesunate for recurrent infection. Five patients in the overall series initially had parasitemia of at least 5% but received only oral artemether-lumefantrine.
Dr. Ridpath distinguished artemisinin partial resistance, which slows parasite clearance, from partner-drug resistance, which typically manifests as late treatment failure. Recurrent infections sometimes resulted in severe disease, and failures occurred after travel to areas without known artemisinin resistance.
Approximately 2,000 malaria diagnoses are reported annually in the U.S., almost all travel-related, although locally acquired cases also occur, Dr. Ridpath said. She also highlighted challenges in U.S. malaria care, including unfamiliarity with malaria, limited diagnostic capacity, limited drug availability and barriers related to health care access and cost.
Suspected malaria requires urgent evaluation with thick and thin blood smears, and treatment should begin immediately after laboratory diagnosis, she said. Any manifestation of severe malaria, or parasitemia of at least 5%, warrants intravenous artesunate regardless of species, followed by a complete oral antimalarial regimen.
Dr. Hamer disclosed serving as an adviser or consultant to Pfizer. Dr. Jacobson reported no financial relationships to disclose. Dr. Ridpath disclosed stock or bond holdings in Amgen, Immunic, Johnson & Johnson, Merck, Pfizer and Protagonist Therapeutics.